Overview
Pyloric-gland type adenoma of the gallbladder is characterized by glandular proliferation resembling pyloric glands of the stomach, often exhibiting mixed biliary and gastric differentiation. 1Diagnosis
Morphological Assessment: Identification of glandular structures resembling pyloric glands.
Immunohistochemical Markers:
- MUC6: Highly expressed in all cases (100%).
- M-GGMC-1: Expressed in 93% of cases.
- MUC5AC and HGM: Present in 38% and 50% of cases, respectively, indicating gastric differentiation.
- CD10: Positive in 34% of cases, suggesting biliary differentiation.
- MUC2: Not expressed in any case.
Proliferation Markers: Evaluation of p53 and Ki-67 for assessing cellular proliferation.
CDX2 Expression: Positive when ≥10% of cells are stained. 1Management
Surgical Resection: Primary treatment, typically involving cholecystectomy to ensure complete removal. 1 (Evidence: Expert opinion)
Follow-Up: Regular monitoring post-surgery to detect recurrence or progression. 1 (Evidence: Expert opinion)Special Populations
No Specific Data: Limited information provided regarding management in pregnancy, pediatrics, elderly, or comorbid conditions. 1Key Recommendations
Utilize immunohistochemical markers such as MUC6, M-GGMC-1, MUC5AC, HGM, and CD10 for accurate diagnosis and differentiation of pyloric-gland type adenomas. (Evidence: Moderate) 1
Surgical resection (cholecystectomy) is recommended as the primary treatment modality for pyloric-gland type adenomas of the gallbladder. (Evidence: Expert opinion) 1
Implement regular follow-up protocols post-surgery to monitor for recurrence or complications. (Evidence: Expert opinion) 1References
1 Nagata S, Ajioka Y, Nishikura K, Watanabe G, Inoue T, Yamaguchi K et al.. Co-expression of gastric and biliary phenotype in pyloric-gland type adenoma of the gallbladder: immunohistochemical analysis of mucin profile and CD10. Oncology reports 2007. link